Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside

Area of Science:

• Immunology
• Nephrology
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by loss of self-tolerance.
• Lupus nephritis (LN), a severe complication of SLE, impacts up to 60% of patients, significantly increasing morbidity and mortality.
• Understanding the genetic and molecular underpinnings of SLE and LN is crucial for developing novel therapeutic interventions.

Purpose of the Study:

• To review current knowledge on the pathogenesis of lupus nephritis.
• To explore emerging and future therapeutic strategies for managing LN.
• To highlight the shift from traditional B-cell-focused treatments to multi-pathway approaches.

Main Methods:

• Review of current literature on SLE and LN pathogenesis.
• Analysis of recent clinical trial data for novel LN therapies.
• Synthesis of information on genetic and molecular mechanisms driving kidney autoimmunity.

Main Results:

• Recent insights reveal multiple extrarenal and intrarenal pathways contributing to LN pathogenesis beyond B-cell involvement.
• Clinical trials evaluating add-on therapies like voclosporin, belimumab, and Obinutuzumab show promising results.
• These findings challenge the traditional induction-maintenance treatment paradigm.

Conclusions:

• A comprehensive understanding of diverse pathogenic pathways is essential for refining individualized treatment and prognostic assessments in LN.
• Novel therapeutic strategies targeting multiple pathways are transforming LN management.
• Future research should continue to explore these pathways for optimized patient outcomes.